Fresenius Kabi Oncology Limited

Fresenius Kabi Oncology Limited, established in 2003, is a wholly owned subsidiary of Fresenius Kabi, a global healthcare company specializing in lifesaving medicines and technologies for infusion, transfusion, and clinical nutrition. The company is headquartered in Gurugram, Haryana, India, with its registered office located at B-310, Som Datt Chambers-1, Bhikaji Cama Place, New Delhi-110066, India. The Corporate Identification Number (CIN) is U24231DL2003PLC119441. The company employs approximately 1,152 individuals. For more information, visit their official website at www.fresenius-kabi-oncology.com.

Fresenius Kabi Oncology Limited operates two primary manufacturing facilities in India. The Baddi plant in Himachal Pradesh specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The Kalyani facility in West Bengal focuses on the manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates. Both facilities adhere to stringent quality management systems and comply with current Good Manufacturing Practices (cGMP) to ensure the safety and efficacy of their products.

The leadership team at Fresenius Kabi Oncology Limited includes:

• Mr. Eduardo Ricardo Santos Montanha: Non-Executive Chairman
• Mr. Nikhil Kulshreshtha: Head of Legal, Compliance Officer, Company Secretary, and Whole-Time Director since 2007
• Mr. Michael Schonhofen: Non-Executive Director since 2008
• Mr. Rakesh Bhargava: Non-Executive Director since 2008
• Mr. Rajiv Lochan Jain: Non-Executive Independent Director since 2013
• Mr. Karsten Peter Lerch: Non-Executive Director since 2018
• Mr. Steffen Georg Roser: Non-Executive Director
• Ms. Heike Susanne Van Dawen: Non-Executive Director
• Mr. Maximilian Alexander Boehmer: Non-Executive Director
• Mr. Phaisal Sirisinsuk: Director of Dabur Pharma (Thailand) Company Ltd since 2003

These leaders bring a wealth of experience and expertise to the company's strategic direction and operations.

Fresenius Kabi Oncology Limited has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals for its finished pharmaceutical formulations from various regulatory bodies, ensuring compliance with international standards. In the United States, the company has faced regulatory scrutiny, with warning letters issued by the FDA in December 2017 for facilities in Kalyani and Baddi. These letters highlighted violations of current Good Manufacturing Practices (cGMP), leading to corrective actions and improvements in manufacturing processes. Despite these challenges, Fresenius Kabi Oncology Limited continues to supply products to the U.S. market, demonstrating resilience and commitment to quality.

Fresenius Kabi Oncology Limited has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's commitment to quality is endorsed by regulatory authorities such as the Therapeutic Goods Administration (TGA) in Australia, the European Directorate for the Quality of Medicines & HealthCare (EDQM), and the U.S. Food and Drug Administration (FDA). These certifications facilitate access to various markets, enabling the company to provide affordable and effective oncology treatments to a broader patient population.

Fresenius Kabi Oncology Limited's geographic strategy involves a balanced approach to market diversification and risk management. While the company has a strong presence in regulated markets, it continues to expand into emerging markets, leveraging its quality certifications to gain market access. This strategic direction aims to mitigate concentration risks and enhance the company's global footprint, ensuring sustainable growth and resilience in the competitive pharmaceutical industry.

Fresenius Kabi Oncology Limited's facilities have been subject to inspections by the U.S. Food and Drug Administration (FDA). In May 2017, the FDA inspected the Kalyani facility in West Bengal, leading to a warning letter issued in December 2017. Similarly, the Baddi facility in Himachal Pradesh was inspected in April 2017, resulting in another warning letter in December 2017. These inspections identified violations of current Good Manufacturing Practices (cGMP), prompting the company to implement corrective actions to address the issues raised. Despite these challenges, Fresenius Kabi Oncology Limited continues to supply products to the U.S. market, demonstrating its commitment to compliance and quality.

Fresenius Kabi Oncology Limited's manufacturing facilities adhere to stringent quality management systems and comply with current Good Manufacturing Practices (cGMP) as endorsed by regulatory authorities such as the Therapeutic Goods Administration (TGA) in Australia, the European Directorate for the Quality of Medicines & HealthCare (EDQM), and the U.S. Food and Drug Administration (FDA). These certifications facilitate access to various markets, enabling the company to provide affordable and effective oncology treatments to a broader patient population.

Fresenius Kabi Oncology Limited operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing facilities hold the necessary licenses and approvals from the CDSCO, ensuring compliance with national standards for pharmaceutical manufacturing. Additionally, the company obtains export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT) to facilitate international trade. These regulatory compliances underscore the company's commitment to maintaining high-quality manufacturing practices and adhering to both domestic and international standards.

In December 2017, the U.S. Food and Drug Administration (FDA) issued warning letters to Fresenius Kabi Oncology Limited for its facilities in Kalyani and Baddi, India. The warning letters cited violations of current Good Manufacturing Practices (cGMP), including inadequate investigations into unexplained discrepancies and sterility failures. The company has since implemented corrective actions to address these issues and has continued to supply products to the U.S. market, demonstrating its commitment to compliance and quality.

Fresenius Kabi Oncology Limited operates in a competitive landscape, with several key players in the oncology generics segment. The company's top competitors include multinational pharmaceutical companies and specialized oncology firms that offer similar product portfolios. Fresenius Kabi Oncology Limited distinguishes itself through its comprehensive product range, including injectables, oral cytotoxics, cytostatics, intermediates, and Active Pharmaceutical Ingredients (APIs). The company's commitment to quality, as endorsed by regulatory authorities such as the Therapeutic Goods Administration (TGA), European Directorate for the Quality of Medicines & HealthCare (EDQM), and U.S. Food and Drug Administration (FDA), further strengthens its position in the market.

Fresenius Kabi Oncology Limited's key differentiators include its comprehensive product portfolio, which spans injectables, oral cytotoxics, cytostatics, intermediates, and Active Pharmaceutical Ingredients (APIs). The company's commitment to quality is demonstrated through adherence to current Good Manufacturing Practices (cGMP) and certifications from regulatory authorities such as the Therapeutic Goods Administration (TGA), European Directorate for the Quality of Medicines & HealthCare (EDQM), and U.S. Food and Drug Administration (FDA). Additionally, the company's global reach and focus on emerging markets enable it to provide affordable and effective oncology treatments to a broad patient population.

Fresenius Kabi Oncology Limited's current strategic direction focuses on expanding its presence in both regulated and emerging markets. The company's product portfolio includes generics, specialty drugs, and biosimilars, with a strong emphasis on oncology treatments. The company continues to invest in research and development to enhance its product offerings and maintain a competitive edge in the market. Future outlooks suggest a continued focus on quality, compliance, and global expansion to meet the growing demand for affordable and effective cancer therapies.

Fresenius Kabi Oncology Limited has a track record of supplying high-quality pharmaceutical products globally. The company's export